Compare GCO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | ADCT |
|---|---|---|
| Founded | 1924 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 431.2M |
| IPO Year | 1994 | 2019 |
| Metric | GCO | ADCT |
|---|---|---|
| Price | $39.21 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $33.00 | $7.75 |
| AVG Volume (30 Days) | 180.1K | ★ 1.7M |
| Earning Date | 06-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | 30.86 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $2,606,898,000.00 | $81,357,000.00 |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $2.12 | $66.49 |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | 13.71 | ★ 14.85 |
| 52 Week Low | $19.62 | $1.02 |
| 52 Week High | $40.39 | $4.98 |
| Indicator | GCO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 11.51 |
| Support Level | $30.06 | N/A |
| Resistance Level | N/A | $4.77 |
| Average True Range (ATR) | 2.13 | 0.19 |
| MACD | 0.25 | -0.26 |
| Stochastic Oscillator | 82.94 | 5.36 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).